Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

AP News

BioMarin jumps on late-stage trial results

NEW YORK (AP) — Shares of BioMarin Pharmaceuticals Inc. jumped to an all-time high Monday after the company said an experimental treatment for a rare genetic disease called Morquio A Syndrome succeeded in a late-stage clinical trial.

BioMarin said patients who were treated with its drug GALNS, or BMN-110, had a larger improvement in the distance they could walk in six minutes. It said patients who took the drug for 24 weeks also had greater stair-climbing speed, greater improvements in lung function, and lower levels of a type of carbohydrate in their urine. BioMarin expects to file for marketing approval of GALNS in the first quarter of 2013.

Shares of BioMarin rose $11.09, or 30 percent, to $48.50 in afternoon trading. Earlier the stock peaked at $49.52, an all-time high.

Morquio A Syndrome, or mucopolysaccharidosis IV-A, is a genetic disease in which the body does not produce enough of the GALNS enzyme, and a compound called keratan sulfate builds up in organs and tissues. Morquio A Syndrome causes skeletal and joint problems and shortness, and can also cause hearing loss, clouded vision and heart valve disease.

BioMarin makes two drugs that treat other types of the disease: Naglazyme, a treatment for mucopolysaccharidosis VI, and Aldurazyme, a treatment for mucopolysaccharidosis I.

blog comments powered by Disqus